If you or someone you care for develops shingles, the single most important thing to know is this: antiviral treatment must begin within 72 hours of the rash appearing, and ideally within 48 hours. That narrow window determines whether the virus is stopped in its tracks or whether it causes lasting nerve damage known as postherpetic neuralgia, a condition that can persist for months or even years. For older adults and those with cognitive decline, the stakes are even higher — chronic pain from PHN can worsen confusion, disrupt sleep, and accelerate functional decline in people already living with dementia. Consider a 74-year-old woman living in assisted care who notices a burning sensation on her left side on a Friday evening. By Monday, the rash has spread and blistered.
She has now crossed the 72-hour threshold, and her chances of developing prolonged nerve pain have increased substantially. Roughly 75 percent of shingles patients aged 70 and older go on to develop postherpetic neuralgia. That weekend delay, which might seem minor for other conditions, can define the trajectory of her pain for the next year. This article covers why the treatment window matters so much, which antiviral medications work best, how postherpetic neuralgia develops and who is most at risk, and what options exist when nerve pain persists despite early treatment. We will also look at the Shingrix vaccine, emerging therapies including deep brain stimulation research, and what caregivers of people with dementia need to watch for.
Table of Contents
- Why Is the 72-Hour Treatment Window So Critical for Shingles Nerve Pain?
- Which Antiviral Medications Work Best, and What Are Their Limitations?
- Who Develops Postherpetic Neuralgia, and Why Does Age Matter So Much?
- Treating Postherpetic Neuralgia — Comparing Medications and Non-Drug Approaches
- Emerging Treatments and the Limits of What We Know
- Why the Shingrix Vaccine Is the Best Defense, Especially for Older Adults
- What Caregivers Should Watch For Going Forward
- Conclusion
- Frequently Asked Questions
Why Is the 72-Hour Treatment Window So Critical for Shingles Nerve Pain?
The varicella-zoster virus, the same virus that causes chickenpox, lies dormant in nerve tissue for decades. When it reactivates as shingles, it travels along nerve fibers to the skin, causing inflammation and damage along the way. Antiviral medications work by halting viral replication, but they cannot repair nerve damage that has already occurred. That is why timing matters more than almost anything else in shingles treatment. The CDC states that controlled studies have only evaluated antiviral efficacy when treatment is initiated within 48 to 72 hours of rash onset. Every hour beyond that window allows the virus to inflict more harm on the nerve pathways. There is a meaningful difference even within that window.
Starting antivirals within 48 hours yields the best outcomes — faster rash resolution and significantly lower rates of ongoing pain. However, observational studies have shown that antivirals can still reduce pain when started beyond 72 hours, particularly in patients with severe symptoms or complications such as eye involvement. So if the window has technically closed, treatment may still be worth pursuing. The point is not to give up after 72 hours, but to understand that the first two to three days represent the period when treatment can do the most good. For people with dementia, the challenge is that they may not be able to describe their symptoms clearly. A person with moderate Alzheimer’s disease might become more agitated or stop eating without anyone realizing that a painful rash is developing under clothing. Caregivers who notice sudden behavioral changes — increased restlessness, guarding one side of the body, or flinching when touched — should check for skin changes immediately. In these situations, hours genuinely matter.
Which Antiviral Medications Work Best, and What Are Their Limitations?
Three FDA-approved antivirals are used for shingles: acyclovir, valacyclovir, and famciclovir. While all three suppress viral replication, they are not equivalent in practice. Valacyclovir, dosed at 1,000 mg three times daily for seven days, and famciclovir, dosed at 500 mg three times daily for seven days, are preferred over acyclovir for a straightforward reason — they require fewer daily doses and achieve better drug levels in the body. Acyclovir requires 800 mg taken five times per day for seven to ten days, a schedule that is difficult for anyone to follow and nearly impossible for a person with cognitive impairment who cannot manage their own medications. Valacyclovir has demonstrated a specific advantage beyond convenience. Research has found it superior to acyclovir in shortening the median time to resolution of shingles-associated pain, even though both medications cleared the rash at similar rates.
this distinction matters because the rash is temporary, but the pain is what threatens quality of life in the weeks and months that follow. For most clinicians treating older adults, valacyclovir is the default choice unless kidney function requires dose adjustment. However, none of these medications are a guarantee against postherpetic neuralgia. Even with prompt treatment, some patients — especially those over 60 — will develop persistent nerve pain. Antivirals reduce the risk and severity, but they do not eliminate it. Patients and caregivers should not assume that starting medication means the problem is solved. Close follow-up after the acute phase is essential, particularly for monitoring pain that persists beyond the time the rash has healed.
Who Develops Postherpetic Neuralgia, and Why Does Age Matter So Much?
Postherpetic neuralgia is the most feared complication of shingles. It occurs in 10 to 18 percent of all shingles patients, but that overall number obscures a sharp age gradient. Among patients aged 50 and older, roughly 13 percent develop PHN. At age 60, the rate climbs to approximately 60 percent. By age 70, it reaches about 75 percent. This is not a minor side effect — it is a condition where burning, stabbing, or electric-shock-like pain continues in the area where the rash appeared, sometimes for years after the skin has completely healed. The reason age plays such a decisive role is that the immune system weakens with each passing decade, a process called immunosenescence.
An older person’s immune response is slower to contain the virus, allowing it more time to damage nerve fibers before antivirals take effect. This is compounded in people with dementia, many of whom also have other conditions that suppress immune function — diabetes, chronic kidney disease, or the physiological stress that comes with long-term cognitive decline. Approximately one million new cases of shingles occur in the United States each year, and one in three Americans will develop shingles at some point. Women face higher incidence rates than men, at 5.2 versus 3.7 per 1,000 person-years. For a person already living with dementia, developing PHN can be catastrophic in ways that go beyond the pain itself. Chronic uncontrolled pain is associated with increased agitation, worsening cognitive function, refusal to eat, and social withdrawal. A care partner might notice that their loved one has become suddenly more confused or aggressive without connecting it to pain that the person cannot articulate. This is why shingles in a dementia patient should be treated as an urgent medical event, not simply a dermatological nuisance.
Treating Postherpetic Neuralgia — Comparing Medications and Non-Drug Approaches
When PHN develops, treatment shifts from antiviral therapy to pain management. The first-line medications are tricyclic antidepressants such as amitriptyline, the anticonvulsants gabapentin and pregabalin, and topical 5 percent lidocaine patches. Each of these works differently. Tricyclic antidepressants modulate pain signaling in the spinal cord and brain. Gabapentin and pregabalin calm overactive nerve firing. Lidocaine patches numb the affected skin area directly. In practice, clinicians often combine approaches — a systemic medication for overall pain reduction and a lidocaine patch for localized flares.
The tradeoffs are real, especially for older adults. A 2025 comparative study found that drug treatments reduced pain more effectively at 12 months but caused more dizziness and sleepiness, while non-drug methods primarily led to localized skin reactions. For someone with dementia, medications that cause drowsiness or dizziness create fall risks and can deepen confusion. Gabapentin, for instance, is on the Beers Criteria list of medications that warrant caution in older adults. Tricyclic antidepressants can cause urinary retention, dry mouth, and cardiac conduction changes. A geriatrician or pain specialist who understands the patient’s full clinical picture is essential for navigating these choices. Lidocaine patches represent perhaps the safest starting point for dementia patients because systemic absorption is minimal and side effects are largely limited to skin irritation at the patch site. They will not resolve severe PHN on their own, but they offer a meaningful reduction in day-to-day discomfort with very little cognitive or systemic cost.
Emerging Treatments and the Limits of What We Know
For patients whose PHN resists standard treatments, newer interventional approaches are being studied. Pulsed radiofrequency of the dorsal root ganglion, known as PRF of the DRG, is considered the most promising interventional approach based on 2025 research. This technique uses electromagnetic energy to modulate pain signaling at the nerve root level without destroying tissue. It has shown benefit in refractory cases, though access is limited and long-term data are still accumulating. At the cutting edge, UCSF is currently testing implanted deep brain stimulation devices and noninvasive magnetic stimulation for treatment-resistant neuropathic pain in clinical trials running through 2025 and 2026.
These approaches target the brain’s own pain-processing circuits rather than the peripheral nerves. For dementia patients, the applicability is uncertain — deep brain stimulation requires patient cooperation for calibration and follow-up, which may be difficult in someone with significant cognitive impairment. Noninvasive magnetic stimulation may prove more practical, but trial results are not yet available. The honest limitation here is that once PHN is established and severe, there is no reliable cure. Treatment aims to reduce pain to a tolerable level, not to eliminate it entirely. This reality underscores why prevention — through vaccination and rapid antiviral treatment — is far more effective than trying to manage the aftermath.
Why the Shingrix Vaccine Is the Best Defense, Especially for Older Adults
The Shingrix vaccine, a two-dose recombinant series, remains the most effective tool for preventing shingles and PHN. In clinical trials, it was 97 percent effective in adults aged 50 to 69 and 91 percent effective in adults 70 and older at preventing shingles. Real-world effectiveness is somewhat lower, as expected — approximately 74 percent effective against shingles and 84 percent effective against PHN in adults over 50, according to a CIDRAP-reported study.
Protection remains at least 85 percent for up to four years and stays high for at least seven years after the two-dose series. Even in immunocompromised individuals, effectiveness ranges from 68 to 91 percent depending on the underlying condition. For families caring for a loved one with dementia, getting the Shingrix vaccine administered before cognitive decline makes self-advocacy difficult is one of the most protective steps available. If your family member has not been vaccinated and is over 50, discuss it with their physician now, not after a shingles outbreak forces the conversation.
What Caregivers Should Watch For Going Forward
The intersection of shingles and dementia care will become increasingly relevant as the population ages. Shingles incidence rises steeply with age — from 1.2 per 1,000 people in their twenties to 32.6 per 1,000 in those over 80 — and the dementia population skews heavily toward those same age groups. As research into noninvasive brain stimulation and targeted nerve therapies progresses, new options may emerge for managing PHN in patients who cannot tolerate systemic medications. For now, the best strategy combines vaccination before vulnerability sets in, vigilant monitoring for early rash symptoms, and immediate medical attention within hours rather than days when shingles is suspected.
Caregivers should keep a simple protocol in mind: any new rash in an older adult, especially one that follows a band-like pattern on one side of the body, should prompt a same-day medical evaluation. Document the time you first notice the rash. Take a photograph. Call the physician’s office and use the word “shingles” to convey urgency. These small actions can mean the difference between a painful week and a painful year.
Conclusion
Shingles is not simply a skin condition. It is a neurological event with a narrow window for effective intervention. Antiviral treatment within 72 hours — and preferably within 48 — can significantly reduce the risk of postherpetic neuralgia, a complication that affects up to 75 percent of shingles patients over 70 and causes pain lasting months to years.
For people living with dementia, who may be unable to report their symptoms, the burden falls on caregivers and medical teams to recognize the signs early and act immediately. Prevention through the Shingrix vaccine remains the strongest defense, with real-world effectiveness of 84 percent against PHN. When shingles does occur, valacyclovir is the preferred antiviral, and pain management for PHN should be tailored carefully to avoid medications that worsen cognitive function or increase fall risk. The research pipeline offers some hope for refractory cases, but the most powerful intervention available today costs nothing more than awareness and speed.
Frequently Asked Questions
Can you still get antiviral treatment if the shingles rash appeared more than 72 hours ago?
Yes. While controlled studies evaluated efficacy within the 48-to-72-hour window, observational data show antivirals can still reduce pain severity when started later, especially in patients with severe symptoms, new lesions still forming, or complications involving the eye or ear. Talk to a doctor even if the rash appeared days ago.
How can I tell if a person with dementia has shingles when they cannot describe their pain?
Watch for sudden behavioral changes — increased agitation, guarding or flinching on one side of the body, refusal to be dressed or bathed, facial grimacing, or disrupted sleep. Physically examine the skin daily in areas the person seems to be protecting. A band-like rash on one side of the torso, face, or neck is the hallmark sign.
Is the Shingrix vaccine safe for people with dementia?
Shingrix is a non-live recombinant vaccine and is generally safe for older adults regardless of cognitive status. Common side effects include injection site soreness and brief fatigue. There are no known interactions with Alzheimer’s medications. The vaccine requires two doses, given two to six months apart.
What is the difference between shingles pain and postherpetic neuralgia?
Shingles pain occurs during the active rash and is caused by viral inflammation of the nerve. Postherpetic neuralgia is pain that persists after the rash has healed, typically defined as pain lasting more than 90 days after rash onset. PHN results from nerve damage caused by the virus and can continue for months to years.
Does gabapentin for PHN worsen dementia symptoms?
Gabapentin can cause drowsiness, dizziness, and cognitive dulling, which may mimic or worsen dementia symptoms. It is on the Beers Criteria list for medications that require caution in older adults. A geriatrician may start at a very low dose and monitor closely, or may choose topical lidocaine patches as a safer alternative for mild to moderate PHN pain.
